[Recurrent uveitis and therapy with monoclonal antibody (daclizumab)].
OBJECTIVE
Assess the efficacy of monoclonal antibody (daclizumab) therapy in the treatment of patients with non-infectious uveitis who do not respond to other immunosuppressive agents.


METHODS
Ten patients with non-infectious intermediate and posterior uveitis were treated with intravenous daclizumab (humanized anti-IL-2 receptor monoclonal antibody) monthly for two years.


RESULTS
70% of the patients have had some improvement in their inflammatory activity being maintained without recurrence. 10% of the patients improved their visual acuity in two lines and the macular edema decreased. 20% of the patients continued to have recurrences, but not worse than the year before. 40% of the patients gave up having the treatment with corticosteroids and 30% with minimum dose (5 mg). No secondary effects were noted during the treatment.


CONCLUSIONS
Daclizumab is effective and safe for long-term use in the treatment of uveitis which cannot be kept under control by other treatments. In time, it allows the dose of corticosteroids to be decreased or even discontinued.
Hernández Garfella
M L
ML
Servicio de Oftalmología, Consorcio Hospital General, Valencia, Spain. jjortiz@ono.com
Díaz Llopis
M
M
Salom Alonso
D
D
Cervera Taulet
E
E
D000293:Adolescent; D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000077561:Daclizumab; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D014605:Uveitis / Q000188:drug therapy*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D000077561:Daclizumab